ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

2-Bromo-3a,5,6,6a-tetrahydro-furo[2,3-c]pyrrol-4-one → 2-[8-(4-Morpholin-4-yl-phenylamino)-imidazo[1,2-a]pyrazin5-yl]-5,6-dihydro-furo[2,3-c]pyrrol-4-one

HRID 1366219
ノート
印刷プレビュー

反応式

HRID 1366219 の反応式
[N:1]1([C:7]2[CH:12]=[CH:11][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:27]=[CH:28][N:29]=4)[C:17](C4C=NNC=4C#N)=[CH:18][N:19]=3)=[CH:9][CH:8]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.C(OC(=O)N(C1C=CC(N2CCOCC2)=CC=1)C1C2N(C=CN=2)C([Sn](CCCC)(CCCC)CCCC)=CN=1)(C)(C)C.Br[C:73]1[O:81][CH:76]2[CH2:77][NH:78][C:79](=[O:80])[CH:75]2[CH:74]=1>CN(C=O)C.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[N:1]1([C:7]2[CH:8]=[CH:9][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:27]=[CH:28][N:29]=4)[C:17]([C:73]4[O:81][C:76]5[CH2:77][NH:78][C:79](=[O:80])[C:75]=5[CH:74]=4)=[CH:18][N:19]=3)=[CH:11][CH:12]=2)[CH2:2][CH2:3][O:4][CH2:5][CH2:6]1
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 3

HCID 590230212-Bromo-3a,5,6,6a-tetrahydro-furo[2,3-c]pyrrol-4-oneHCID 590230864-[8-(4-Morpholin-4-yl-phenylamino)-imidazo[1,2-a]pyrazin-5-yl]-2H-pyrazole-3-carbonitrileHCID 59023110(4-Morpholin-4-yl-phenyl)-(5-tributylstannanyl-imidazo[1,2-a]pyrazin-8-yl)-carbamic acid tert-butyl ester

生成物 1

HCID 590229852-[8-(4-Morpholin-4-yl-phenylamino)-imidazo[1,2-a]pyrazin5-yl]-5,6-dihydro-furo[2,3-c]pyrrol-4-one収率 64%

試薬・触媒・溶媒 2

HCID 178418397HCID 178418397、化合物触媒HCID 6228Dimethylformamide溶媒

実験手順

In the same way as described for Compound 212, step 3 using (4-morpholin-4-yl-phenyl)-(5-tributylstannanyl-imidazo[1,2-a]pyrazin-8-yl)-carbamic acid tert-butyl ester (255 mg, 0.373 mmol), 2-bromo-3a,5,6,6a-tetrahydro-furo[2,3-c]pyrrol-4-one (50 mg, 0.249 mmol) and Pd(PPh3)4 (29 mg, 0.0249 mmol) in DMF (3 mL). The reaction mixture is concentrated in vacuo and the residue dissolved in 1:1 DCM:TFA (drop of H2O) and stirred at room temperature for 3 hours. The mixture is partitioned between ethyl acetate and sat. NaHCO3 and the aqueous layer is extracted with ethyl acetate (3×). The organic layers are combined, dried over MgSO4, filtered and concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with DCM followed by a 97:3 mixture DCM:NH3 (7M in MeOH). The fractions containing the desired compound are concentrated in vacuo to give a solid which is triturated with diethyl ether to afford the title compound (66.3 mg, 64%). Conversion of the compound into the mesylate salt using 1M MsOH (0.16 mL) affords the title product as a solid (69.3 mg, 87%). LCMS: Rt 2.52 min (99%), m/z (APCI) 417 (M+H)+, 1H-NMR (400 MHz, d6-DMSO) δ (ppm). 2.36 (3H, s, MsOH), 3.25 (4H, m), 3.84 (4H, m), 4.52 (2H, s), 7.18 (2H, br s), 7.40 (1H, s), 7.83 (1H, s), 7.90 (3H, m), 8.21 (1H, br s), 8.44 (1H, s), 10.25 (1H, br s).

後処理

  1. concentrationThe reaction mixture is concentrated in vacuo
  2. dissolutionthe residue dissolved in 1:1 DCM
  3. customThe mixture is partitioned between ethyl acetate and sat. NaHCO3
  4. extractionthe aqueous layer is extracted with ethyl acetate (3×)
  5. dry with materialdried over MgSO4
  6. filtrationfiltered
  7. concentrationconcentrated in vacuo
  8. customThe residue is purified by silica gel column chromatography
  9. washeluting with DCM
  10. additionThe fractions containing the desired compound
  11. concentrationare concentrated in vacuo
  12. customto give a solid which
  13. customis triturated with diethyl ether

出典と根拠

ORDレコード
ord-034b781eb8134efe8b9a0eaf0b51fcea
出典データセット
uspto-grants-2011_02
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07893058B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート